Bionoid Pharma Inc
AI Maverick Intel, Inc., an AI company, focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. Its technology streamlines the customer acquisition process by automating two way communication and data-driven engagement with its clients ideal audience segments across healthcare, biotech, and other sectors. The company was formerly known as Bionoid Pharma Inc. an… Read more
Bionoid Pharma Inc (BINP) - Total Liabilities
Latest total liabilities as of June 2025: $150.31K USD
Based on the latest financial reports, Bionoid Pharma Inc (BINP) has total liabilities worth $150.31K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bionoid Pharma Inc - Total Liabilities Trend (2006–2023)
This chart illustrates how Bionoid Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bionoid Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Bionoid Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xtreme One Entertainment, Inc.
PINK:XONI
|
USA | $2.43 Million |
|
IDT INTL
MU:IIN
|
Germany | €389.17 Million |
|
Santeon Group Inc
PINK:SANT
|
USA | $918.86K |
|
Werth Holz SA
WAR:WHH
|
Poland | zł23.31 Million |
|
Jarvis Securities
LSE:JIM
|
UK | GBX3.25 Million |
|
Reebonz Holding Ltd
PINK:RBZHF
|
USA | $65.10 Million |
|
ABC COMMUNICATIONS
BE:ABM
|
Germany | €224.01 Million |
|
Republic Glass Holdings Corp
PSE:REG
|
Philippines | ₱195.71 Million |
Liability Composition Analysis (2006–2023)
This chart breaks down Bionoid Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bionoid Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bionoid Pharma Inc (2006–2023)
The table below shows the annual total liabilities of Bionoid Pharma Inc from 2006 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $154.88K | -2.82% |
| 2022-12-31 | $159.38K | -1.64% |
| 2021-12-31 | $162.03K | -1.58% |
| 2020-12-31 | $164.64K | +43.62% |
| 2019-12-31 | $114.64K | +8845.25% |
| 2013-12-31 | $1.28K | -99.90% |
| 2011-12-31 | $1.25 Million | -43.23% |
| 2010-12-31 | $2.20 Million | +16.37% |
| 2009-12-31 | $1.89 Million | -1.56% |
| 2008-12-31 | $1.92 Million | +41.71% |
| 2007-12-31 | $1.36 Million | +122.84% |
| 2006-12-31 | $608.43K | -- |